Telomere Extension via mRNA — Gene Therapy & Genetic Interventions
Transient mRNA delivery of TERT to extend telomeres without permanent genetic modification or cancer risk.
Overview
Researchers at Stanford (Helen Blau lab) developed a method to extend telomeres by delivering modified mRNA encoding TERT (telomerase reverse transcriptase) to human cells. A single transfection rapidly extended telomeres by up to 1,000 base pairs and increased proliferative capacity by 28 additional population doublings. Crucially, TERT expression is transient (~48 hours), avoiding the cancer risk associated with constitutive telomerase activation. The approach has been demonstrated in human fibroblasts, myoblasts, and iPSC-derived cells. Turn Biotechnologies is developing this approach commercially.
Indications
- Cellular senescence reversal (ex vivo and in vivo)
- Dyskeratosis congenita and telomere biology disorders
- Idiopathic pulmonary fibrosis
- Age-related muscle wasting (sarcopenia)
- Cell therapy manufacturing (extend donor cell replicative capacity)
Mechanism of Action
Modified TERT mRNA is delivered to cells via lipid-mediated transfection or LNP, avoiding genomic integration
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Modified TERT mRNA | 1-2 mcg per treatment | 3 treatments over 3 days (in vitro) | Ex vivo protocol; in vivo dosing not established |
| LNP-TERT mRNA (investigational) | Study-specific | Periodic (weeks to months) | In vivo delivery under development |
Evidence Grade
GRADE C
Safety & Contraindications
- Transient expression (~48h) limits oncogenic risk vs. permanent gene therapy
- Repeated treatments needed for sustained effect
- mRNA delivery efficiency varies by cell type and tissue
- In vivo delivery to specific tissues remains challenging
- Modified mRNA avoids innate immune activation from unmodified mRNA
- No human clinical trials for anti-aging telomere extension